A Study Comparing Degu Insulin Liraglutide Injection With Premixed Insulin on the Prognosis of Diabetes Mellitus

A randomized open, positive parallel controlled clinical study design was adopted. Participants were randomly assigned 1:1 according to inclusion criteria and exclusion criteria into two treatment regiments: Delu insulin liraglupeptide injection group and premixed insulin (or premixed insulin analogue). After fasting blood glucose was controlled at 7.5mmol /l in the morning, blood glucose was monitored by CGM (14d), and the Time in Range (3.9-10 mmol/l) was compared. Glycated albumin was measured and stool samples were taken before treatment and at 4 weeks.

NCT Number	NCT06925334
Lead Sponsor	Beijing Tsinghua Chang Gung Hospital Collaborators: Taizhou First People's Hospital, Wenzhou Central Hospital, Wenzhou People's Hospital, Chaohu Hospital of Anhui Medical University, Affiliated Zhoushan Hospital of Wenzhou Medical University, Yiwu Central Hospital, Jinhua Municipal Central Hospital, Dongyang People's Hospital, The Central Hospital of Lishui City, Affiliated Hospital of Jiaxing University, Jinhua People's Hospital, Wuhu City Second People's Hospital, Affiliated Hospital of Nantong University
Conditions	Type 2 Diabetic Patients
Enrollment	170 participants
Start Date	2024-05-20
Primary Completion	2025-12-31 (estimated)
Study Completion	2025-12-31 (estimated)
Updated on ClinicalTrials.gov	2025-04-13